middle.news
Noxopharm Advances SOF-SKN with US FDA Pre-IND Meeting Request
9:34am on Tuesday 7th of July, 2026 AEST
•
Biotechnology
Read Story
Noxopharm Advances SOF-SKN with US FDA Pre-IND Meeting Request
9:34am on Tuesday 7th of July, 2026 AEST
Key Points
Pre-IND meeting scheduled in two months
SOF-SKN targets cutaneous lupus erythematosus
Meeting to clarify clinical and manufacturing plans
Sofra platform underpins broad autoimmune potential
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE